These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12695544)

  • 1. Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha.
    Renodon-Cornière A; Sørensen TK; Jensen PB; Nitiss JL; Søkilde B; Sehested M; Jensen LH
    Mol Pharmacol; 2003 May; 63(5):1159-68. PubMed ID: 12695544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
    Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
    Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance.
    Jensen LH; Wessel I; Møller M; Nitiss JL; Sehested M; Jensen PB
    FEBS Lett; 2000 Sep; 480(2-3):201-7. PubMed ID: 11034329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II.
    Sorensen TK; Grauslund M; Jensen PB; Sehested M; Jensen LH
    Biochem Biophys Res Commun; 2005 Sep; 334(3):853-60. PubMed ID: 16053917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site.
    Hasinoff BB; Creighton AM; Kozlowska H; Thampatty P; Allan WP; Yalowich JC
    Mol Pharmacol; 1997 Nov; 52(5):839-45. PubMed ID: 9351975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of human DNA topoisomerase II alpha with DNA: quantification by surface plasmon resonance.
    Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M
    Biochemistry; 2002 Nov; 41(45):13395-402. PubMed ID: 12416984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
    Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M
    Biochemistry; 2003 Aug; 42(32):9749-54. PubMed ID: 12911317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane).
    Hasinoff BB; Kuschak TI; Yalowich JC; Creighton AM
    Biochem Pharmacol; 1995 Sep; 50(7):953-8. PubMed ID: 7575679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines.
    Jensen LH; Nitiss KC; Rose A; Dong J; Zhou J; Hu T; Osheroff N; Jensen PB; Sehested M; Nitiss JL
    J Biol Chem; 2000 Jan; 275(3):2137-46. PubMed ID: 10636919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187.
    Classen S; Olland S; Berger JM
    Proc Natl Acad Sci U S A; 2003 Sep; 100(19):10629-34. PubMed ID: 12963818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp.
    Roca J; Ishida R; Berger JM; Andoh T; Wang JC
    Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1781-5. PubMed ID: 8127881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha.
    Wessel I; Jensen LH; Renodon-Corniere A; Sorensen TK; Nitiss JL; Jensen PB; Sehested M
    FEBS Lett; 2002 Jun; 520(1-3):161-6. PubMed ID: 12044890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
    van Hille B; Etiévant C; Barret JM; Kruczynski A; Hill BT
    Anticancer Drugs; 2000 Nov; 11(10):829-41. PubMed ID: 11142691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
    Ishida R; Hamatake M; Wasserman RA; Nitiss JL; Wang JC; Andoh T
    Cancer Res; 1995 Jun; 55(11):2299-303. PubMed ID: 7757979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis.
    Vaughn J; Huang S; Wessel I; Sorensen TK; Hsieh T; Jensen LH; Jensen PB; Sehested M; Nitiss JL
    J Biol Chem; 2005 Mar; 280(12):11920-9. PubMed ID: 15647268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
    Hasinoff BB; Patel D; Wu X
    Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
    BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of the DNA topoisomerase II catalytic inhibitor meso-2,3-bis(3,5-dioxopiperazine-1-yl)butane (ICRF-193), a bisdioxopiperazine derivative, with the conserved region(s) of eukaryotic but not prokaryotic enzyme.
    Sato M; Ishida R; Narita T; Kato J; Ikeda H; Fukazawa H; Andoh T
    Biochem Pharmacol; 1997 Sep; 54(5):545-50. PubMed ID: 9337070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.